SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.
3D Nasal Cast Model
For Admin
Translational Research
Business
A Leading Company in Nasal Drug Delivery
June 26, 2023
TOKYO and KAGOSHIMA, Japan, June 26, 2023 – Shin Nippon Biomedical Laboratories, Ltd. (TSE Prime: 2395, Chairman and President: Ryoichi Nagata, M.D., Ph.D., “SNBL”) is pleased to announce that the results of its collaboration research with Prof. Yasuhiro Magata, Ph.D. from the Department of Molecular Imaging of the Institute for Medical Photonics Research at Hamamatsu University School of Medicine, have been published in the Journal of Controlled Release (JCR), an authoritative scientific...
May 19, 2023
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) (Nasdaq: STSA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS1011). Today, Satsuma announced that its 505(b)(2) new drug application (NDA) for STS101, a novel and investigational...
April 17, 2023
SNBL today announced that it has entered into a definitive agreement to acquire Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) (Nasdaq: STSA). Satsuma has been developing STS1011), a migraine drug based on SNBL’s proprietary intranasal delivery platform technology and has completed Phase III clinical trials and submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (“FDA”) in March 2023. With the acquisition of Satsuma, SNBL will acquire...
November 14, 2022
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) (Nasdaq: STSA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS1011). Today, Satsuma announced topline results from the STS101 SUMMIT Phase 3 efficacy trial for acute treatment of...
September 21, 2022
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) (Nasdaq: STSA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS1011). Today, Satsuma announced positive safety, tolerability and efficacy results from its recent analysis of the...
August 02, 2021
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) (Nasdaq: STSA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS1011). Today, Satsuma announced randomization of the first subject in its SUMMIT Phase 3 efficacy trial of STS101 for...
June 17, 2021
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) (Nasdaq: STSA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS1011). Satsuma today announced positive PK, tolerability, and safety results from a Phase 1 trial of 5.2mg and to greater...